Lataa...
Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study
Background. There is a need to prevent or minimize bone loss associated with antiretroviral treatment (ART) initiation. We compared maraviroc (MVC)- to tenofovir disoproxil fumarate (TDF)–containing ART. Methods. This was a double-blind, placebo-controlled trial. ART-naive subjects with human immuno...
Tallennettuna:
| Julkaisussa: | Clin Infect Dis |
|---|---|
| Päätekijät: | , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Oxford University Press
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4560904/ https://ncbi.nlm.nih.gov/pubmed/26060295 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ455 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|